Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice

Journal of Clinical Investigation

Volumn 119, Issue 6, 2009, Pages 1626-1637

  Korf, Hannelie ^a   Vander Beken, Seppe ^b   Romano, Marta ^a   Steffensen, Knut R ^c   Stijlemans, Benoît ^d   Gustafsson, Jan Åke ^c,e   Grooten, Johan ^b   Huygen, Kris ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c KAROLINSKA INSTITUTE   (Sweden)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; GLYCOPROTEIN P 15095; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; GRANULOMATOUS INFLAMMATION; IMMUNE RESPONSE; INFECTION SENSITIVITY; INNATE IMMUNITY; LUNG ALVEOLUS CELL; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANIMALS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; IMMUNITY, INNATE; KINETICS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TUBERCULOSIS, PULMONARY;

EID: 67650996739     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35288     Document Type: Article

References (57)

1. WHO. 2005. Tuberculosis [fact sheet]. Revised March 2007. http://www.who.int/mediacentre/factsheets/fs104/en.
2. Manabe, Y.C., and Bishai, W.R. 2000. Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting. Nat. Med. 6:1327-1329.
3. Rengarajan, J., Bloom, B.R., and Rubin, E.J. 2005. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc. Natl. Acad. Sci. U. S. A. 102:8327-8332.
4. Schnappinger, D., et al. 2003. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J. Exp. Med. 198:693-704.
5. Voskuil, M.I., et al. 2003. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 198:705-713.
6. Bloch, H., and Segal, W. 1956. Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J. Bacteriol. 72:132-141.
7. Wheeler, P.R., and Ratledge, C. 1988. Use of carbon sources for lipid biosynthesis in Mycobacterium leprae: a comparison with other pathogenic mycobacteria. J. Gen. Microbiol. 134:2111-2121.
8. Ehrt, S., and Schnappinger, D. 2007. Mycobacterium tuberculosis virulence: lipids inside and out. Nat. Med. 13:284-285.
9. McKinney, J.D., et al. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 406:735-738.
10. Kendall, S.L., et al. 2007. A highly conserved transcriptional repressor controls a large regulon involved in lipid degradation in Mycobacterium smegmatis and Mycobacterium tuberculosis. Mol. Microbiol. 65:684-699.
11. Van der Geize, R., et al. 2007. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc. Natl. Acad. Sci. U. S. A. 104:1947-1952.
12. Pandey, A.K., and Sassetti, C.M. 2008. Mycobacterial persistence requires the utilization of host cholesterol. Proc. Natl. Acad. Sci. U. S. A. 105:4376-4380.
13. Gatfield, J., and Pieters, J. 2000. Essential role for cholesterol in entry of mycobacteria into macrophages. Science. 288:1647-1650.
14. Peyron, P., Bordier, C., N'Diaye, E.N., and Maridonneau-Parini, I. 2000. Nonopsonic phagocytosis of Mycobacterium kansasii by human neutrophils depends on cholesterol and is mediated by CR3 associated with glycosylphosphatidylinositol-anchored proteins. J. Immunol. 165:5186-5191.
15. de Chastellier, C., and Thilo, L. 2006. Cholesterol depletion in Mycobacterium avium-infected macrophages overcomes the block in phagosome maturation and leads to the reversible sequestration of viable mycobacteria in phagolysosome-derived autophagic vacuoles. Cell. Microbiol. 8:242-256.
16. Korf, J., Stoltz, A., Verschoor, J., De Baetselier, P., and Grooten, J. 2005. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur. J. Immunol. 35:890-900.
17. Ordway, D., Henao-Tamayo, M., Orme, I.M., and Gonzalez-Juarrero, M. 2005. Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family. J. Immunol. 175:3873-3881.
18. Hunter, R.L., Jagannath, C., and Actor, J.K. 2007. Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb.). 87:267-278.
19. Peyron, P., et al. 2008. Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog. 4:e1000204.
20. Ricote, M., Valledor, A.F., and Glass, C.K. 2004. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24:230-239.
21. Valledor, A.F. 2005. The innate immune response under the control of the LXR pathway. Immunobiology. 210:127-132.
22. Mitro, N., et al. 2007. The nuclear receptor LXR is a glucose sensor. Nature. 445:219-223.
23. Janowski, B.A., Willy, P.J., Devi, T.R., Falck, J.R., and Mangelsdorf, D.J. 1996. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 383:728-731.
24. Lehmann, J.M., et al. 1997. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272:3137-3140.
25. Fu, X., et al. 2001. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276:38378-38387.
26. Repa, J.J., and Mangelsdorf, D.J. 2000. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16:459-481.
27. Chawla, A., Repa, J.J., Evans, R.M., and Mangelsdorf, D.J. 2001. Nuclear receptors and lipid physiology: opening the X-files. Science. 294:1866-1870.
28. Repa, J.J., et al. 2000. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 289:1524-1529.
29. Venkateswaran, A., et al. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. U. S. A. 97:12097-12102.
30. Castrillo, A., and Tontonoz, P. 2004. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 20:455-480.
31. Joseph, S.B., Castrillo, A., Laffitte, B.A., Mangelsdorf, D.J., and Tontonoz, P. 2003. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9:213-219.
32. Joseph, S.B., et al. 2004. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell. 119:299-309.
33. Castrillo, A., et al. 2003. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell. 12:805-816.
34. Fontaine, C., et al. 2007. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ. Res. 101:40-49.
35. Valledor, A.F., et al. 2004. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc. Natl. Acad. Sci. U. S. A. 101:17813-17818.
36. Collins, J.L. 2004. Therapeutic opportunities for liver X receptor modulators. Curr. Opin. Drug Discov. Devel. 7:692-702.
37. Vermaelen, K., and Pauwels, R. 2004. Accurate and simple discrimination of mouse pulmonary dendritic cell and macrophage populations by flow cytometry: methodology and new insights. Cytometry A. 61:170-177.
38. Rausch, P.G., Pryzwansky, K.B., Spitznagel, J.K., and Herion, J.C. 1978. Immunocytochemical identification of abnormal polymorphonuclear neutrophils in patients with leukemia. Blood Cells. 4:369-382.
39. Smith, E., et al. 2007. IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice. J. Immunol. 179:8274-8279.
40. Goerdt, S., and Orfanos, C.E. 1999. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity. 10:137-142.
41. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3:23-35.
42. Nair, M.G., Cochrane, D.W., and Allen, J.E. 2003. Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. Immunol. Lett. 85:173-180.
43. Raes, G., et al. 2002. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J. Leukoc. Biol. 71:597-602.
44. Kahnert, A., et al. 2006. Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur. J. Immunol. 36:631-647.
45. Pedrosa, J., et al. 2000. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect. Immun. 68:577-583.
46. Seiler, P., et al. 2000. Rapid neutrophil response controls fast-replicating intracellular bacteria but not slow-replicating Mycobacterium tuberculosis. J. Infect. Dis. 181:671-680.
47. Laan, M., et al. 1999. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 162:2347-2352.
48. Khader, S.A., et al. 2007. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8:369-377.
49. Smoak, K., et al. 2008. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J. Immunol. 180:3305- 3312.
50. Bramlett, K.S., et al. 2003. A natural product ligand of the oxysterol receptor, liver X receptor. J. Pharmacol. Exp. Ther. 307:291-296.
51. Korf, J.E., et al. 2006. Macrophage reprogramming by mycolic acid promotes a tolerogenic response in experimental asthma. Am. J. Respir. Crit. Care Med. 174:152-160.
52. Perez-Guzman, C., and Vargas, M.H. 2006. Hypocholesterolemia: a major risk factor for developing pulmonary tuberculosis? Med. Hypotheses. 66:1227-1230.
53. Martens, G.W., et al. 2008. Hypercholesterolemia impairs immunity to tuberculosis. Infect. Immun. 76:3464-3472.
54. Alberti, S., et al. 2001. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXR-beta-deficient mice. J. Clin. Invest. 107:565-573.
55. Tanghe, A., et al. 2001. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 69:3041-3047.
56. Snewin, V.A., et al. 1999. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect. Immun. 67:4586-4593.
57. Tracy, R.E., and Walia, P. 2004. Lipid fixation for fat staining in paraffin sections applied to lesions of atherosclerosis. Virchows Arch. 445:22-26.